Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical Compositions for Preventing and Treating Th1 or Th2 mediated Immune Disease Comprising 4H3MC(4-Hydroxy-3-methoxycinnamaldehyde) as an Active Ingredient

a technology of th1 or th2mediated immune disease and active ingredient, which is applied in the direction of pharmaceutical delivery mechanism, medical preparations, edible oils/fats, etc., can solve the problems of undeveloped therapeutic agent against t-cell-mediated disease, which targets pkc, and the effect of 4h3mc, a cinnamic acid derivative, on the activation of t cells,

Inactive Publication Date: 2017-09-07
GWANGJU INST OF SCI & TECH
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent describes a new ingredient called 4H3MC (4-hydroxy-3-methoxycinnamaldehyde) that can prevent or treat immune-related diseases, specifically allergic and atopic skin diseases. This ingredient can be used in both pharmaceutical and cosmetic compositions. The functional food and cosmetic compositions contain 4H3MC as an active ingredient and help inhibit T cell activity and the protein kinase C (PKC) activity of T cells. This ingredient has been found to be safe and effective in animal models. The compositions can be administered orally or applied topically and can be formulated with other food or cosmetic ingredients to make them more palatable and user-friendly. The patent provides technical evidence for the use of 4H3MC in preventing or treating immune-related diseases and offers new opportunities for developing functional food and cosmetic compositions.

Problems solved by technology

These autoreactive lead to target organ and tissue damages, which are exaggerated by elevated T cell cytokines even after antigen clearance [2].
However, a therapeutic agent against T-cell-mediated disease, which targets PKC, has not yet been developed.
However, the effect of 4H3MC, a cinnamic acid derivative, on the activation of T cells, has not yet been found.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical Compositions for Preventing and Treating Th1 or Th2 mediated Immune Disease Comprising 4H3MC(4-Hydroxy-3-methoxycinnamaldehyde) as an Active Ingredient
  • Pharmaceutical Compositions for Preventing and Treating Th1 or Th2 mediated Immune Disease Comprising 4H3MC(4-Hydroxy-3-methoxycinnamaldehyde) as an Active Ingredient
  • Pharmaceutical Compositions for Preventing and Treating Th1 or Th2 mediated Immune Disease Comprising 4H3MC(4-Hydroxy-3-methoxycinnamaldehyde) as an Active Ingredient

Examples

Experimental program
Comparison scheme
Effect test

examples

[0051]Materials and Methods

[0052]Cell Culture

[0053]Jurkat T cells (ATCC, CRL-1651, Manassas, Va.) and Raji B cells (ATCC, CCL-86) were cultured in RPMI complete medium supplemented with 10% fetal bovine serum (FBS, AusGeneX, Santa Clara, Calif.) and PenStrep (Gibco-RBL). After written informed consent, human peripheral blood leukocytes (PBL) were isolated from healthy donors by a sedimentation method using dextran and Ficoll Amersham Biosciences, Piscataway, N.J.). All the cell lines and cells used in the present invention were cultured at 37° C. in a humidified incubator containing 5% CO2. All experiments using human peripheral blood leukocytes were approved by the Ethics Committee of the School of Life Sciences, GIST.

[0054]Reagents and Antibodies

[0055]4-Hydroxy-3-methoxycinnamaldehyde (4H3MC; PubChem CID: 5280536) and p-hydroxycinnamic acid (HCA; PubChem CID: 637542) with the purity over 99% were provided by Professor Seung-Ho Lee from Yeungnam University (Korea). For treatment in...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
concentrationsaaaaaaaaaa
concentrationsaaaaaaaaaa
pHaaaaaaaaaa
Login to View More

Abstract

The present invention relates to a pharmaceutical composition for preventing or treating Th1- or Th2-mediated disease, which comprises 4H3MC (4-hydroxy-3-methoxycinnamaldehyde) as an active ingredient. 4H3MC (4-hydroxy-3-methoxycinnamaldehyde) according to the present invention shows the effect of inhibiting T-cell activity without inducing T-cell death. Thus, 4H3MC (4-hydroxy-3-methoxycinnamaldehyde) according to the present invention can be developed into an effective therapeutic agent against Th1- or Th2-mediated disease, etc.

Description

BACKGROUND OF THE INVENTION[0001]Field of the Invention[0002]The present invention relates to a pharmaceutical composition for preventing or treating Th1- or Th2-mediated immune disease, which comprises 4H3MC (4-hydroxy-3-methoxycinnamaldehyde) as an active ingredient.DESCRIPTION OF THE RELATED ART[0003]T cell-mediated immune responses known as adaptive immunity develop antigen-specific T cells for eradiation of pathogens and malignant cells. In addition, T cell-mediated immune responses can also include atypical recognition of autoantigens, leading to autoimmune diseases [1]. These autoreactive lead to target organ and tissue damages, which are exaggerated by elevated T cell cytokines even after antigen clearance [2]. Thus, modulation of T cell responses is a central approach to develop autoimmune disease therapeutic agents.[0004]When T cells are stimulated by antigen-presenting cells, the T cells are activated and a signal is transmitted into the cells. In this process, protein ki...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/11A23L33/10A61K9/00
CPCA61K31/11A23V2002/00A23L33/10A61K9/0056A23D9/00A23L33/105Y02A50/30
Inventor JUN, CHANG-DUKAKBER, UROOSLEE, HYUN SU
Owner GWANGJU INST OF SCI & TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com